Blood Stream Infections
Conditions
Brief summary
The current study is a pilot study to assess the feasibility of a superordinate project. The final objective of this superordinate project is to describe and model the pharmacokinetic behaviour of a small number of standard antimicrobials used in the treatment of frequent blood stream infections, and to link this via pharmacodynamic models to (inhibition of) bacterial or fungal growth as well as to clinical outcomes in patients.
Detailed description
Patients with a high probability of a blood stream infection and an indication for antimicrobial treatment will be included. The study comprises the identification of patients as potential study participants, obtaining informed consent, documentation of available potential covariates from patient file, withdrawal of pre-study blood samples (PK, PD, microbiology) including documentation of exact time of sampling and processing of the samples, first drug administration including exact documentation (as part of patient care; not as a study intervention), withdrawal of subsequent blood samples (PK, PD, microbiology) during the next 3 days including documentation of exact time of sampling and processing of the samples, storage of processed samples for further analysis, and, if possible, documentation of patient outcome after 7 days. The following steps are carried out after completion of the clinical part of the study in the individual patient or, when possible, in all patients together or in a subset: Bioanalytics, DNA Counts, assessing primary and secondary study endpoints, pharmacometric analyses including PK parameter estimation, PD parameter estimation and assessment of covariate effects with regard to DNA count, CRP, IL-6 and procalcitonin.
Interventions
Blood samples will be taken to assess antimicrobial drug concentrations and microbial DNA blood counts. Per patient, at least 5 and up to 15 samples for drug concentrations and at least 3 and up to 6 samples for DNA counts are taken for a duration of up to 3 days.
Sponsors
University of Witten/Herdecke
University of Leipzig
University Hospital Munich
University of Cologne
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* High probability of a blood stream infection; this is based on * the presence of SIRS \[Bone et al. 1992\] defined by more than one of the following clinical manifestations: 1. a body temperature greater than 38°C or less than 36°C 2. a heart rate greater than 90 beats per minute 3. tachypnea, manifested by a respiratory rate greater than 20 breaths per minute, or hyperventilation, as indicated by a PaCO2 of less than 32 mm Hg 4. an alteration in the white blood cell count, such as a count greater than 12,000/µl, a count less than 4,000/µl, or the presence of more than 10 percent immature neutrophils (bands). and * the assessment of the treating physician according to the patient's situation that the SIRS is caused by an infection (e.g., patients after treatment with cytotoxic drugs) * indication for antimicrobial treatment * Intended use of one of the following antimicrobial agents: piperacillin/tazobactam; vancomycin; meropenem; ampicillin/sulbactam; flucloxacillin; ceftriaxone; caspofungin (according to the decision of the project coordinator, use of other antimicrobial agents may also be included if anticipated to be used frequently) * Age: 18 years or older (no upper limit) * Willing and capable to provide written consent prior to enrolment after ample information has been provided
Exclusion criteria
* expected chances to successfully carry out venipunctures to obtain the blood samples required for the study are inadequately low according to the assessment of the physician * Anemia CTCAE grade \>2 (i.e., Hb \<8.0 g/dL / 4.9 mmol/L) * the clinical status of the patients suggests that the anticipated treatment of the patient or other conditions would make participation on the study inappropriate (e.g., terminally ill patients); the respective assessment is done by the treating physician
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Fraction of eligible patients | Screening | Fraction of identified and potentially eligible patients willing and able to provide informed consent |
| Positive blood microbial DNA count | Samples for DNA counts are taken for a duration of up to 3 days. | Fraction of study participants having any positive blood microbial DNA count for microbes which does not reflect sample contamination |
| Fraction of patients with at least three samples with microbial DNA | Samples for DNA counts are taken for a duration of up to 3 days. | Fraction of study participants with at least three samples with quantifiable microbial DNA along with a proper documentation |
| Plausible time courses of antimicrobial drug concentrations | Samples for antimicrobial drug concentrations are taken for a duration of up to 3 days. | Fraction of study participants with plausible time courses of antimicrobial drug concentrations along with a proper documentation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Population pharmacokinetic parameters of drugs studied | Samples for antimicrobial drug concentrations are taken for a duration of up to 3 days. | Pharmacometric analyses including PK parameter estimation |
| Population pharmacodynamic parameters of drugs studied | Samples for antimicrobial drug concentrations are taken for a duration of up to 3 days. | Population pharmacodynamic parameters of drugs studied with regard to bacterial DNA count, procalcitonin, IL-6 and C-reactive protein |
Countries
Germany
Contacts
Primary ContactUwe Fuhr, Prof. Dr.
Backup ContactDario Zaremba, Dr.
Outcome results
None listed